Keywords: reassuring, cv, safety, ph, iiib, cycloset, trial
Reassuring CV safety from Ph IIIb Cycloset trial
Article | 02 July 2007
VeroScience, a privately-held biotechnology firm, and its partner, fellow USA-based S2 Therapeutics, have reported results from a Phase IIIb clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
